• Orbik Cybersecurity

  Participated · Equity · May 2026

  Founded in 2023 and based in Arrasate-Mondragón (Basque Country), Orbik Cybersecurity develops product cybersecurity and regulatory compliance solutions for industry and embedded electronics. The company operates an accredited laboratory that performs certified cybersecurity validation against standards such as IEC 62443, CRA, ISO 21434, IEC 63452, ETSI EN 303 645 and FDA requirements, and offers a cloud-based SaaS platform (myorbik.com) for end-to-end product cybersecurity management. In 2025 Orbik launched Orbik Virtual Lab, a virtual laboratory to validate, test, and certify product security in controlled digital environments. The company reported more than €2 million in revenue in 2025 and has grown its team to over 50 professionals; it converted to a hybrid worker cooperative in 2025 with support from MONDRAGON, IKERLAN and the Basque Government. Orbik plans to scale operations, invest in R&D, expand into new markets and sectors, grow the team to about 65 people, and add 100 new clients as part of its roadmap toward 2030.

• wooptix

  Participated · Series C · Feb 2025

  Wooptix builds semiconductor metrology systems based on wavefront phase imaging, a technique adapted from adaptive optics research in astronomy. Its flagship product, Phemet®, delivers industry-leading lateral resolution, near real-time process capability and can collect over 16 million data points with sub-nanometer height resolution. Phemet® has been adopted by major semiconductor manufacturers and is on track for full automation and factory-floor deployment for in-line testing in the coming months. The company says its tools rapidly and accurately detect nanoscale defects, addressing growing precision and efficiency demands driven by AI and advanced chip designs. Wooptix has an international presence across Europe, the United States and Asia, with offices in Tenerife, Madrid and San Francisco and headquarters in Spain. The new funding will accelerate product development, expand international reach and scale the team to meet growing industry demand. Wooptix commercializes semiconductor metrology equipment built around its patented Phemet® wavefront phase‑imaging sensor, which measures blank and patterned wafer shape and warpage with higher resolution and in less time than incumbent systems. The company says Phemet® attains nanometer‑scale sensitivity while remaining transportable (about a metric ton), enabling lab and fab deployments. Wooptix plans to automate Phemet® to reduce contamination risk and improve measurement reproducibility, and to integrate the system into existing semiconductor tools from vendors. The business is transitioning from R&D toward product and manufacturing, building infrastructure, procedures, and certifications to support customers as it begins initial tool deliveries. Financially, Wooptix announced a €10 million Series B and was awarded a €2.5 million EIC Accelerator grant that will support product introduction and further technological innovation. The company operates from Tenerife, Madrid, and San Francisco and was founded in 2014. Wooptix is a spin‑off of the University of La Laguna (Tenerife) led by inventor José Manuel Rodríguez Ramos and co‑founders Javier Párraga (CEO) and Javier Elizalde. Its core product, Natural3D, is an image‑processing technology that can produce 3D images and video from standard cameras and has been demonstrated in the astrophysics field. The technology is positioned for applications across smartphones, industrial and professional cameras, medical uses, consumer electronics, augmented reality and high‑precision industrial measurement. Investors have described the company as having a patented product and an experienced engineering team in imaging and optics. Wooptix closed a €3 million financing round that will be used to perfect Natural3D, evaluate new applications and begin commercial development. Erik Jorgensen (Intel Capital) and Javier Ulecia (Bullnet) are set to join the company’s board alongside the co‑founders.

• inBiot Monitoring

  Led · Equity · Jun 2024

  inBiot, founded in 2018, develops proprietary technology and digital services for monitoring and controlling indoor air quality in buildings. Its smart devices provide real-time data, integrate with ventilation and HVAC systems, help optimize operations, and contribute to energy savings while facilitating international environmental certifications. The company has installed devices across a wide variety of buildings throughout Spain and began international expansion last year into markets such as the UK and Ireland. inBiot currently employs 19 technical professionals (9 women) and expects to grow to 28 employees within three years. The business emphasizes research and development and sustainability and positions itself as a national reference in indoor air quality monitoring. With the new capital the company intends to consolidate its market presence and accelerate further international expansion.

• Cocoon Bioscience

  Led · Equity · Nov 2023

  Cocoon Bioscience develops and manufactures specialized enzymes and high-performance growth factors for pharmaceutical, biological-sciences and alternative-protein industries. Its CrisBio® technology automates insect chrysalis systems, using live insects as natural bioreactors to produce enzymes for mRNA synthesis and genetic sequencing and growth factors for cultivated meat at lower cost than other protein-expression platforms. The company says its development significantly reduces production costs and enables industrialization of these biotechnologies. Cocoon offers bespoke, on-demand protein production services and aims to be a long-term partner as customers scale processes and products. Due to strong customer demand, the firm plans to build a new, more efficient manufacturing plant at Parque Tecnológico de Bizkaia in Zamudio to scale CrisBio® to kilogram-per-year production. Proceeds from the financing will be used to expand production capacity, invest in product and process innovation, and strengthen the company. Cocoon Bioscience, born from the split of Algenex after its sale to Insud Pharma in 2022, develops biocomponents including specialized enzymes for mRNA synthesis and genome sequencing and high‑performance growth factors for the alternative‑protein industry. The company also supplies enzymes for the pharmaceutical market. Cocoon’s products target emerging global markets with significant potential. The €15M funding will be used to rapidly scale Cocoon’s platform to industrial levels. Cocoon plans a new production plant in Zamudio (Vizcaya), and when that facility is at full capacity in two to three years the company anticipates revenues of up to €80 million. The financing is intended to accelerate industrialization and commercialization of its enzyme and growth‑factor portfolio.

• Multiverse Computing

  Participated · Seed · Oct 2021

  Founded in 2019 in San Sebastián, Multiverse Computing builds AI solutions inspired by quantum computing techniques—notably tensor-network approaches—to compress large language models and produce energy-efficient AI. The company says its technology can reduce model size and energy use by up to 95%, deliver 4x–12x faster inference, and cut costs by 50%–80%, enabling deployment on constrained devices like smartphones, laptops and satellites. Multiverse has launched a new generation of optimized models, including an open-source model and a family of compressed models designed for resource-limited environments. It has formed strategic partnerships with firms such as Cohere, Axelera AI, Plain Concepts, Inetum, EY and PwC to accelerate adoption in finance, energy, logistics, space, health and defense. Financially, Multiverse closed a €189M Series B in June 2025 (led by Bullhound Capital and including SETT and other investors) and is currently finalizing a larger round that could total €500M, backed in part by a €107M SETT commitment.

No current team members are available.